PA8849601A1 - Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos - Google Patents
Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismosInfo
- Publication number
- PA8849601A1 PA8849601A1 PA20098849601A PA8849601A PA8849601A1 PA 8849601 A1 PA8849601 A1 PA 8849601A1 PA 20098849601 A PA20098849601 A PA 20098849601A PA 8849601 A PA8849601 A PA 8849601A PA 8849601 A1 PA8849601 A1 PA 8849601A1
- Authority
- PA
- Panama
- Prior art keywords
- monoclonal antibodies
- ferroportina
- same
- count
- reticulocite
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12007608P | 2008-12-05 | 2008-12-05 | |
| US23981809P | 2009-09-04 | 2009-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PA8849601A1 true PA8849601A1 (es) | 2010-07-27 |
Family
ID=41683589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PA20098849601A PA8849601A1 (es) | 2008-12-05 | 2009-11-23 | Anticuerpos monoclonales anti-ferroportina 1 y usos de los mismos |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP2373335B1 (enExample) |
| JP (1) | JP5713917B2 (enExample) |
| KR (1) | KR101353117B1 (enExample) |
| CN (1) | CN102238962B (enExample) |
| AR (1) | AR074398A1 (enExample) |
| AU (1) | AU2009322587B2 (enExample) |
| BR (1) | BRPI0922288A2 (enExample) |
| CA (1) | CA2745618C (enExample) |
| CY (1) | CY1117355T1 (enExample) |
| DK (1) | DK2373335T3 (enExample) |
| EA (1) | EA020472B1 (enExample) |
| ES (1) | ES2566343T3 (enExample) |
| HR (1) | HRP20160302T1 (enExample) |
| HU (1) | HUE028585T2 (enExample) |
| IL (1) | IL212731A0 (enExample) |
| MX (1) | MX2011005939A (enExample) |
| NZ (1) | NZ592545A (enExample) |
| PA (1) | PA8849601A1 (enExample) |
| PL (1) | PL2373335T3 (enExample) |
| SG (1) | SG171960A1 (enExample) |
| SI (1) | SI2373335T1 (enExample) |
| TW (1) | TW201023891A (enExample) |
| UA (1) | UA104741C2 (enExample) |
| WO (1) | WO2010065496A1 (enExample) |
| ZA (1) | ZA201103941B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014027905A2 (pt) * | 2012-05-14 | 2017-06-27 | Genentech Inc | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. |
| WO2019213016A1 (en) | 2018-04-30 | 2019-11-07 | The Children's Hospital Of Philadelphia | Methods of improving anemias by combining agents |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| CN110806486B (zh) * | 2019-11-23 | 2023-03-21 | 中南大学湘雅三医院 | Mafg/as1/pcbp2/fpn1调控轴作为靶位点检测试剂的应用 |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| CN113980987A (zh) * | 2021-12-06 | 2022-01-28 | 上海市农业科学院 | 一种提高植物抗镍性能的PgIREG1S和AlATP-PRTS双基因组及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166448B1 (en) * | 1999-05-10 | 2007-01-23 | Children's Medical Center Corproation | Ferroportin1 nucleic acids and proteins |
| IT1319221B1 (it) * | 2000-10-17 | 2003-09-26 | Antonello Pietrangelo | Mutazioni nel gene della ferroportina 1 associata ad emocromatosiereditaria. |
| EP2803675A3 (en) * | 2008-01-25 | 2014-12-24 | Amgen, Inc | Ferroportin antibodies and methods of use |
-
2009
- 2009-11-23 PA PA20098849601A patent/PA8849601A1/es unknown
- 2009-11-24 AR ARP090104529A patent/AR074398A1/es unknown
- 2009-11-25 TW TW098140185A patent/TW201023891A/zh unknown
- 2009-12-01 DK DK09760073.8T patent/DK2373335T3/en active
- 2009-12-01 EA EA201170764A patent/EA020472B1/ru not_active IP Right Cessation
- 2009-12-01 MX MX2011005939A patent/MX2011005939A/es active IP Right Grant
- 2009-12-01 ES ES09760073.8T patent/ES2566343T3/es active Active
- 2009-12-01 UA UAA201107028A patent/UA104741C2/uk unknown
- 2009-12-01 KR KR1020117014053A patent/KR101353117B1/ko not_active Expired - Fee Related
- 2009-12-01 JP JP2011539625A patent/JP5713917B2/ja not_active Expired - Fee Related
- 2009-12-01 BR BRPI0922288A patent/BRPI0922288A2/pt not_active IP Right Cessation
- 2009-12-01 SG SG2011040797A patent/SG171960A1/en unknown
- 2009-12-01 NZ NZ592545A patent/NZ592545A/xx not_active IP Right Cessation
- 2009-12-01 AU AU2009322587A patent/AU2009322587B2/en not_active Ceased
- 2009-12-01 EP EP09760073.8A patent/EP2373335B1/en active Active
- 2009-12-01 SI SI200931382T patent/SI2373335T1/sl unknown
- 2009-12-01 PL PL09760073T patent/PL2373335T3/pl unknown
- 2009-12-01 CN CN200980148354.8A patent/CN102238962B/zh not_active Expired - Fee Related
- 2009-12-01 WO PCT/US2009/066187 patent/WO2010065496A1/en not_active Ceased
- 2009-12-01 HR HRP20160302TT patent/HRP20160302T1/hr unknown
- 2009-12-01 CA CA2745618A patent/CA2745618C/en not_active Expired - Fee Related
- 2009-12-01 HU HUE09760073A patent/HUE028585T2/en unknown
-
2011
- 2011-05-05 IL IL212731A patent/IL212731A0/en unknown
- 2011-05-27 ZA ZA2011/03941A patent/ZA201103941B/en unknown
-
2016
- 2016-04-12 CY CY20161100296T patent/CY1117355T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010065496A1 (en) | 2010-06-10 |
| AR074398A1 (es) | 2011-01-12 |
| JP2012510814A (ja) | 2012-05-17 |
| CA2745618C (en) | 2014-06-10 |
| JP5713917B2 (ja) | 2015-05-07 |
| CA2745618A1 (en) | 2010-06-10 |
| AU2009322587A1 (en) | 2011-07-28 |
| EA201170764A1 (ru) | 2011-12-30 |
| HUE028585T2 (en) | 2016-12-28 |
| HK1158977A1 (zh) | 2012-07-27 |
| KR20110084996A (ko) | 2011-07-26 |
| UA104741C2 (uk) | 2014-03-11 |
| AU2009322587B2 (en) | 2013-09-26 |
| CN102238962A (zh) | 2011-11-09 |
| SG171960A1 (en) | 2011-07-28 |
| KR101353117B1 (ko) | 2014-02-17 |
| EP2373335A1 (en) | 2011-10-12 |
| MX2011005939A (es) | 2011-06-27 |
| IL212731A0 (en) | 2011-07-31 |
| TW201023891A (en) | 2010-07-01 |
| PL2373335T3 (pl) | 2016-08-31 |
| SI2373335T1 (sl) | 2016-04-29 |
| HRP20160302T1 (hr) | 2016-04-22 |
| NZ592545A (en) | 2012-12-21 |
| EA020472B1 (ru) | 2014-11-28 |
| ES2566343T3 (es) | 2016-04-12 |
| BRPI0922288A2 (pt) | 2018-08-28 |
| DK2373335T3 (en) | 2016-05-02 |
| CN102238962B (zh) | 2014-02-12 |
| ZA201103941B (en) | 2012-11-28 |
| EP2373335B1 (en) | 2016-02-24 |
| CY1117355T1 (el) | 2017-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122816T1 (el) | Στοχοθετημενοι συνδετικοι παραγοντες εναντι β7-η1 | |
| DOP2020000032A (es) | Proteínas de unión específicas y sus usos | |
| UY33144A (es) | Anticuerpos humanos para proteína 4 de tipo angiopoyetina humana | |
| CY1119283T1 (el) | Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii | |
| UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
| AR073717A1 (es) | Anticuerpos anti-notch2 de murino y humano, y metodos de uso | |
| CY1118668T1 (el) | Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων | |
| MX338971B (es) | Ratones de m-csf humanizada. | |
| EP2595967A4 (en) | TETRAZIN TRANS CYCLOOCTS LIGATION FOR FAST CONSTRUCTION OF RADIONUCLIDED TAGS | |
| PA8849001A1 (es) | Anticuerpos de c-met | |
| CY1118549T1 (el) | Χρηση anti-vegf αντισωματος σε συνδυασμο με χημειοθεραπεια για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
| MX2019002967A (es) | Anticuerpos de union a cd3. | |
| GT200600240A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
| EP2170075A4 (en) | MARKED INHIBITORS OF PROSTATE SPECIFIC MEMBRANEANT (PSMA), BIOLOGICAL ASSESSMENT AND USE AS IMAGING AGENT | |
| EA201390254A1 (ru) | Модифицированные полипептиды релаксина и их применение | |
| ECSP066756A (es) | Anticuerpo monoclonal específico m-csf y los usos del mismo | |
| ES2422739T3 (es) | Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB | |
| CR20110066A (es) | Anticuerpos monoclonales contra el factor tisular inhibidor de la via | |
| EA201070518A1 (ru) | Композиция по уходу за волосами | |
| UA105760C2 (uk) | Антитіло проти bst2 | |
| CL2008003190A1 (es) | Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica. | |
| UY32915A (es) | Proteínas de únión específicas y sus usos | |
| AR062268A1 (es) | Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos | |
| BR112017024091A2 (pt) | métodos para o armazenamento de sangue total e composições do mesmo | |
| CO2020000517A2 (es) | Fragmento fab de anticuerpo anti-ceacam5 de humano novedoso |